journal article·2024-08Open access

Enhanced pyroptosis induction with pore-forming gene delivery for osteosarcoma microenvironment reshaping

Jing-Jun Nie, Bowen Zhang, Peng Luo, Maoguo Luo, Yuwen Luo, Jingjing Cao, Honggang Wang, Jianping Mao, Yonggang Xing, Weifeng Liu, Yuning Cheng, Renxian Wang, Yajun Liu, Xinbao Wu, Xieyuan Jiang, Xiaoguang Cheng, Chi Zhang, Da-Fu Chen

Abstract

Osteosarcoma is the most common malignant bone tumor without efficient management for improving 5-year event-free survival. Immunotherapy is also limited due to its highly immunosuppressive tumor microenvironment (TME). Pore-forming gasdermins (GSDMs)-mediated pyroptosis has gained increasing concern in reshaping TME, however, the expressions and relationships of GSDMs with osteosarcoma remain unclear. Herein, gasdermin E (GSDME) expression is found to be positively correlated with the prognosis and immune infiltration of osteosarcoma patients, and low GSDME expression was observed. A vector termed as LPAD contains abundant hydroxyl groups for hydrating layer formation was then prepared to deliver the GSDME gene to upregulate protein expression in osteosarcoma for efficient TME reshaping via enhanced pyroptosis induction. Atomistic molecular dynamics simulations analysis proved that the hydroxyl groups increased LPAD hydration abilities by enhancing coulombic interaction. The upregulated GSDME expression together with cleaved caspase-3 provided impressive pyroptosis induction. The pyroptosis further initiated proinflammatory cytokines release, increased immune cell infiltration, activated adaptive immune responses and create a favorable immunogenic hot TME. The study not only confirms the role of GSDME in the immune infiltration and prognosis of osteosarcoma, but also provides a promising strategy for the inhibition of osteosarcoma by pore-forming GSDME gene delivery induced enhanced pyroptosis to reshape the TME of osteosarcoma.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · Inflammasome and immune disorders · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (49)

Show source-provided references
2. Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment10.1038/s41413-023-00246-z ↗
3. Next generation of immune checkpoint inhibitors and beyond10.1186/s13045-021-01056-8 ↗
4. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial10.1016/S1470-2045(17)30624-1 ↗
5. Immune microenvironment in osteosarcoma: components, therapeutic strategies and clinical applications
6. Advancing therapy for osteosarcoma10.1038/s41571-021-00519-8 ↗
7. Novel therapeutic strategies for spinal osteosarcomas10.1016/j.semcancer.2019.05.018 ↗
8. New horizons in the treatment of osteosarcoma10.1056/NEJMra2103423 ↗
9. Immunogenic cell stress and death10.1038/s41590-022-01132-2 ↗
10. Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy10.1038/s41392-022-01046-3 ↗
11. Immunogenic cell death in cancer therapy10.1146/annurev-immunol-032712-100008 ↗
12. Immunogenic cell death and DAMPs in cancer therapy10.1038/nrc3380 ↗
13. Calreticulin exposure dictates the immunogenicity of cancer cell death10.1038/nm1523 ↗
14. A bioorthogonal system reveals antitumour immune function of pyroptosis10.1038/s41586-020-2079-1 ↗
15. The gasdermin protein family: emerging roles in gastrointestinal health and disease10.1038/s41575-023-00743-w ↗
16. Streptococcal pyrogenic exotoxin B cleaves GSDMA and triggers pyroptosis10.1038/s41586-021-04384-4 ↗
17. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells10.1126/science.aaz7548 ↗
18. Gasdermin E suppresses tumour growth by activating anti-tumour immunity10.1038/s41586-020-2071-9 ↗
19. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin10.1038/nature22393 ↗
20. Microenvironment-responsive prodrug-induced pyroptosis boosts cancer immunotherapy10.1002/advs.202101840 ↗
21. The metabolite α-KG induces GSDMC-dependent pyroptosis through death receptor 6-activated caspase-810.1038/s41422-021-00506-9 ↗
22. Boosting glioblastoma therapy with targeted pyroptosis induction10.1002/smll.202207604 ↗
23. Engineering 2D multienzyme-mimicking pyroptosis inducers for ultrasound-augmented catalytic tumor nanotherapy10.1002/advs.202301279 ↗
24. Record-high ultrasound-sensitive NO nanogenerators for cascade tumor pyroptosis and immunotherapy10.1002/advs.202302278 ↗
25. Macrophages-based biohybrid microrobots for breast cancer photothermal immunotherapy by inducing pyroptosis
26. Pyroptosis activation by photodynamic-boosted nanocatalytic medicine favors malignancy recession10.1016/j.cej.2022.136030 ↗
27. Pore forming-mediated intracellular protein delivery for enhanced cancer immunotherapy10.1126/sciadv.abq4659 ↗
28. Pyroptosis-mediated synergistic photodynamic and photothermal immunotherapy enabled by a tumor-membrane-targeted photosensitive dimer
29. The current landscape of nucleic acid therapeutics10.1038/s41565-021-00898-0 ↗
30. Cancer-targeting nanoparticles for combinatorial nucleic acid delivery10.1002/adma.201901081 ↗
31. A circular RNA activated by TGFβ promotes tumor metastasis through enhancing IGF2BP3-mediated PDPN mRNA stability10.1038/s41467-023-42571-1 ↗
32. GSH/pH dual activatable cross-linked and fluorinated PEI for cancer gene therapy through endogenous iron de-hijacking and in situ ROS amplification
33. Magnetic-manipulated NK cell proliferation and activation enhance immunotherapy of orthotopic liver cancer10.1021/jacs.3c02049 ↗
34. In vitro prostate cancer treatment via CRISPR-Cas9 gene editing facilitated by polyethyleneimine-derived graphene quantum dots10.1002/adfm.202305506 ↗
35. Synergistic tumor immunological strategy by combining tumor nanovaccine with gene-mediated extracellular matrix scavenger10.1016/j.biomaterials.2020.120114 ↗
36. Remodeling of mitochondrial metabolism by a mitochondria-targeted RNAi nanoplatform for effective cancer therapy
37. Orchestrated yolk-shell nanohybrids regulate macrophage polarization and dendritic cell maturation for oncotherapy with augmented antitumor immunity
38. Controllable star cationic poly(disulfide)s achieve genetically cascade catalytic therapy by delivering bifunctional fusion plasmids10.1002/adma.202307190 ↗
39. Versatile types of hydroxyl-rich polycationic systems via O-heterocyclic ring-opening reactions: from strategic design to nucleic acid delivery applications10.1016/j.progpolymsci.2017.09.003 ↗
40. Charge-reversal nanocomolexes-based CRISPR/Cas9 delivery system for loss-of-function oncogene editing in hepatocellular carcinoma10.1016/j.jconrel.2021.03.030 ↗
41. Versatile types of organic/inorganic nanohybrids: from strategic design to biomedical applications10.1021/acs.chemrev.8b00401 ↗
42. Flexible modulation of cellular activities with cationic photosensitizers: insights of alkyl chain length on reactive oxygen species antimicrobial mechanisms10.1002/adma.202302943 ↗
43. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
44. Tumor microenvironment and therapeutic response10.1016/j.canlet.2016.01.043 ↗
45. Bone microenvironment signals in osteosarcoma development10.1007/s00018-015-1918-y ↗
46. Preparation of polycation with hydroxyls for enhanced delivery of miRNA in osteosarcoma therapy10.1039/D2BM00253A ↗
47. Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs10.1124/dmd.30.2.183 ↗
48. A nobel prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens10.1111/imm.13008 ↗
49. Hallmarks of cancer: the next generation10.1016/j.cell.2011.02.013 ↗